Assorted News from the Last Week: CAC2 Member Regina Karchner (Childhood Brain Cancer Foundation) focuses the light on survivorship as we end Survivorship Month with

Assorted News from the Last Week: Replacing two high-dose chemotherapy courses with blinatumomab (Blincyto) significantly improved event-free survival (EFS) in pediatric patients with newly diagnosed

Assorted News from the Last Week: CAC2 Supporting Organization Blood Cancer United is buying remaining supplies of Luvelta and will manage a compassionate-use program to

Assorted News from the Last Week: AACR issued a Special Edition Advocacy Alert for National Cancer Survivor Month, with several pediatric-focused articles. Children’s brain tumors

Assorted News from the Last Week: The FDA has granted rare pediatric disease designation and orphan drug designation to FL118 for the treatment of patients

Assorted News from the Last Week: Black pediatric AML patients had more than twice the risk of acute kidney injury during treatment as their White

Assorted News from the Last Week: A large number of CAC2 members contributed to the recently published conclusions from the 2024 paediatric strategy forum for

Assorted News from the Last Week: The U.S. Food and Drug Administration (FDA) approved FoundationOne®CDx as a companion diagnostic for Supporting Organization Member Day One

Assorted News from the Last Week: Pope Francis tells pediatric cancer patients they are ‘witnesses of hope.’ Unraveling the relationship between stress exposure and childhood

Assorted News from the Last Week: GLO-BNHL opens first sites of a multi-country platform trial that will offer multiple new treatments and a better chance